Diagonal Bio AB Statistics
Total Valuation
Diagonal Bio AB has a market cap or net worth of SEK 8.17 million. The enterprise value is 6.43 million.
| Market Cap | 8.17M |
| Enterprise Value | 6.43M |
Important Dates
The last earnings date was Friday, October 31, 2025.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Diagonal Bio AB has 1.63 billion shares outstanding. The number of shares has increased by 649.85% in one year.
| Current Share Class | 1.63B |
| Shares Outstanding | 1.63B |
| Shares Change (YoY) | +649.85% |
| Shares Change (QoQ) | +11.13% |
| Owned by Insiders (%) | 9.56% |
| Owned by Institutions (%) | 2.66% |
| Float | 1.44B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.87 |
| PB Ratio | 0.30 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.68 |
| EV / Sales | 4.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.05
| Current Ratio | 2.05 |
| Quick Ratio | 0.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -731.08 |
Financial Efficiency
Return on equity (ROE) is -35.05% and return on invested capital (ROIC) is -22.05%.
| Return on Equity (ROE) | -35.05% |
| Return on Assets (ROA) | -20.32% |
| Return on Invested Capital (ROIC) | -22.05% |
| Return on Capital Employed (ROCE) | -35.24% |
| Revenue Per Employee | 348,250 |
| Profits Per Employee | -2.36M |
| Employee Count | 5 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.98% in the last 52 weeks. The beta is -1.85, so Diagonal Bio AB's price volatility has been lower than the market average.
| Beta (5Y) | -1.85 |
| 52-Week Price Change | -84.98% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 33.39 |
| Average Volume (20 Days) | 10,842,296 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diagonal Bio AB had revenue of SEK 1.39 million and -9.44 million in losses. Loss per share was -0.01.
| Revenue | 1.39M |
| Gross Profit | 958,000 |
| Operating Income | -9.50M |
| Pretax Income | -9.44M |
| Net Income | -9.44M |
| EBITDA | -9.09M |
| EBIT | -9.50M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 1.74 million in cash and n/a in debt, giving a net cash position of 1.74 million or 0.00 per share.
| Cash & Cash Equivalents | 1.74M |
| Total Debt | n/a |
| Net Cash | 1.74M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 26.97M |
| Book Value Per Share | 0.02 |
| Working Capital | 2.24M |
Cash Flow
| Operating Cash Flow | -8.45M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 68.77% |
| Operating Margin | -682.27% |
| Pretax Margin | -677.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Diagonal Bio AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -649.85% |
| Shareholder Yield | -649.85% |
| Earnings Yield | -115.56% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Diagonal Bio AB has an Altman Z-Score of 1.36 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.36 |
| Piotroski F-Score | 3 |